ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

Evercore ISI raised the firm’s price target on ProQR Therapeutics (PRQR) to $5 from $4 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a “notable lengthening” of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.